SCM
BEAM icon

Sterling Capital Management’s Beam Therapeutics BEAM Stock Holding History

Sterling Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.8K Buy
621
+6
+1% +$166 ﹤0.01% 2167
2025
Q4 		$17K Buy
615
+383
+165% +$9.77K ﹤0.01% 2317
2025
Q3 		$5.63K Buy
232
+1
+0.4% +$20 ﹤0.01% 2736
2025
Q2 		$3.93K Sell
231
-1,347
-85% -$23.5K ﹤0.01% 2640
2025
Q1 		$30.8K Sell
1,578
-831
-34% -$21.8K ﹤0.01% 1542
2024
Q4 		$59.7K Buy
2,409
+2,146
+816% +$54.8K ﹤0.01% 1566
2024
Q3 		$6.44K Buy
+263
New +$6.79K ﹤0.01% 1672

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Sterling Capital Management's BEAM Position: Q1 2026 in Review

Sterling Capital Management increased its Beam Therapeutics (BEAM) stake by 0.98% in Q1 2026, buying an estimated $166 and bringing the position to 621 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Sterling Capital Management first reported a position in BEAM in Q3 2024 and has held it in 7 quarters since. The position peaked at $59.7K in Q4 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Sterling Capital Management held 621 shares of Beam Therapeutics worth $14.8K as of Q1 2026.
  • Sterling Capital Management bought 6 Beam Therapeutics shares in Q1 2026, an estimated $166.
  • Beam Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2167 holding.
  • Sterling Capital Management first reported a position in Beam Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Beam Therapeutics position peaked at $59.7K in Q4 2024.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.